厄洛替尼诱发一名男性胰腺癌患者出现睫毛粗长症。

Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.

作者信息

Saif Muhammad Wasif, Gnanaraj Joseph

机构信息

Gastrointestinal Cancers Program, Yale Cancer Center, and Yale University School of Medicine, New Haven, Connecticut 06520, USA.

出版信息

Cutan Ocul Toxicol. 2010 Mar;29(1):62-6. doi: 10.3109/15569520903440058.

DOI:10.3109/15569520903440058

PMID:19954400

Abstract

In this report we present a case of erlotinib-induced trichomegaly in a male patient who received erlotinib for his pancreatic cancer. Trichomegaly as a side effect of epidermal growth factor receptor (EGFR) inhibitor therapy is uncommon in male patients. Also, it has not been reported previously in a patient with pancreatic cancer. Previous reported cases all involved female lung cancer patients. We emphasize the importance of recognizing the side effects of EGFR inhibitor therapy and its implications on the prognosis of the cancer treated.

摘要

在本报告中，我们呈现了一例男性胰腺癌患者使用厄洛替尼后出现睫毛生长异常的病例。睫毛生长异常作为表皮生长因子受体（EGFR）抑制剂治疗的副作用，在男性患者中并不常见。此外，此前尚未有胰腺癌患者出现该副作用的报道。先前报道的病例均为女性肺癌患者。我们强调了认识EGFR抑制剂治疗副作用及其对所治疗癌症预后影响的重要性。